Velocity Clinical Research-Sioux City

Sioux City, Iowa 51106

3 studies enrolling now · 19 studies all time

What they study most

Acute Gastroenteritis, Asthma, COVID-19, Clostridioides Difficile Associated Disease, Cortisol Excess, Epstein-Barr Virus Infection, Influenza, Influenza, Human, Migraine, Norovirus Acute Gastroenteritis, Pediatric Migraine, RESPIRATORY SYNCYTIAL VIRUS (RSV)

Studies at this site

• Randomized Study in Children and Adolescents With Migraine: Acute Treatment — Recruiting now
• Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) — Recruiting now
• A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older — Recruiting now
• A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults — Completed
• Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications — Completed
• Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection — Stopped early
• A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis — Running, not enrolling
• Efficacy and Safety of NVX-CoV2705 — Running, not enrolling
• A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults — Running, not enrolling
• A Study to Evaluate Solriktug in Adult Participants With Asthma — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) — Running, not enrolling
• A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age — Running, not enrolling
• Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine — Completed
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza. — Completed
• To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. — Completed
• A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age — Completed
• A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older — Completed
• The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older — Completed
• A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age — Completed